Erenumab - Amgen/Novartis

Drug Profile

Erenumab - Amgen/Novartis

Alternative Names: Aimovig; AMG 334; Anti-calcitonin-gene-related-peptide-receptor-monoclonal-antibody-Amgen; Anti-CGRP-receptor-monoclonal-antibody-Amgen

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Novartis
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • No development reported Hot flashes

Most Recent Events

  • 18 Apr 2018 Amgen plans a phase I trial for Migraine (In Children and Adolescents) in USA (NCT03499119)
  • 17 Apr 2018 Adverse events data from the phase III LIBERTY trial in Migraine released by Amgen
  • 17 Apr 2018 Updated efficacy data from the phase III LIBERTY trial in Migraine released by Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top